The Medical Device Business Journal — Medical Device News & Articles | MassDevice
InVivo Therapeutics (OTC:NVIV) hopes to hear back from the FDA within four weeks about its application to run the first human trials of its biodegradable scaffold for treating traumatic spinal cord injuries, according to CEO Frank Reynolds.
Analysts at Zacks Investment Research see sunnier days ahead for the medical device sector during the second half of 2011, despite lingering economic softness and ongoing pressure on the orthopedic market.
Estimating worldwide sales of roughly $300 billion this year, the researchers peg the U.S. market’s share at about $95 billion in 2010.
